In terms of tumor specificity, PTX at clinically relevant concentrations lacks cancer selectivity (Scribano et al., 2021), whereas CMPD1, at similar low concentrations, specifically induces mitotic defects in breast cancer cells without affecting mitotic fidelity in non-transformed cells (Figure 2, Figure 2—figure supplement 1A–C). The gene discussed is SOX9; the disease is neoplasm.